Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gubra AS's gross profit for the
six
months ended in Dec. 2025 was €14.5 Mil. Gubra AS's gross profit for the trailing twelve months (TTM) ended in Dec. 2025 was €342.7 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Gubra AS's gross profit for the
six
months ended in Dec. 2025 was €14.5 Mil. Gubra AS's Revenue for the
six
months ended in Dec. 2025 was €19.4 Mil. Therefore, Gubra AS's Gross Margin % for the quarter that ended in Dec. 2025 was 74.91%.
Gubra AS had a gross margin of 74.91% for the quarter that ended in Dec. 2025 => Durable competitive advantage
During the past 7 years, the highestGross Margin % of Gubra AS was 96.96%. The lowest was 49.02%. And the median was 58.98%.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Gubra AS had a gross margin of 74.91% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Gubra AS Gross Profit Related Terms
Gubra AS Gross Profit Historical Data
* Premium members only.
The historical data trend for Gubra AS's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PI3 vs VRTX, REGN, RVMD: Gross Profit Comparison
For the Biotechnology subindustry, Gubra AS's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gubra AS Gross Profit vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gubra AS's Gross Profit distribution charts can be found below:
* The bar in red indicates where Gubra AS's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €342.7 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Gubra AS (FRA:PI3) has a Gross Profit of €342.7 Mil as of Dec. 2025. Gross Profit equals net sales less total cost of goods sold. View historical data on Gubra AS and its competitors.
Is Gubra AS's Gross Profit too high?
Gubra AS's current Gross Profit is €342.7 Mil. Overall, Gubra AS has a GF Score™ of 75/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gubra AS's Gross Profit compare to VRTX and REGN?
Gubra AS's Gross Profit of €342.7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Biotechnology company?
A good Gross Profit depends on the Biotechnology industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Gubra AS and its competitors. Gubra AS's current Gross Profit is €342.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gubra AS stock overvalued right now?
Based on GuruFocus' analysis, Gubra AS (FRA:PI3) is currently considered Possible Value Trap. The stock's GF Value™ is €386.89, compared to a current price of €52.15 — trading 86.5% below its estimated fair value. The current Gross Profit is €342.7 Mil. Gubra AS's overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Gubra AS (FRA:PI3), the current Gross Profit is €342.7 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gubra AS (FRA:PI3) Overvalued in 2026?
Based on GuruFocus' analysis, Gubra AS stock appears to be undervalued.
The current stock price of €52.15 is trading 86.5% below its estimated GF Value™ of €386.89.
GuruFocus considers Gubra AS to be Possible Value Trap.
Key valuation signals for FRA:PI3:
Gross Profit: €342.7 Mil
GF Value™: €386.89 vs. price of €52.15 (86.5% below fair value)
No single metric tells the full story. See the FRA:PI3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has two segments: Pre-clinical contract research (CRO), which derives maximum revenue and Biotech Segment. It derives maximum revenue from Pre-clinical contract research (CRO) segment. Geographically, the company operates in Europe, North America and Other regions.
75GF Score
Get the complete analysis for FRA:PI3
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PI3 has been successfully added to your 
